NO20090818L - Humant endogent retrovirus polypeptid sammensetninger samt anvendelsesmetoder derav - Google Patents

Humant endogent retrovirus polypeptid sammensetninger samt anvendelsesmetoder derav

Info

Publication number
NO20090818L
NO20090818L NO20090818A NO20090818A NO20090818L NO 20090818 L NO20090818 L NO 20090818L NO 20090818 A NO20090818 A NO 20090818A NO 20090818 A NO20090818 A NO 20090818A NO 20090818 L NO20090818 L NO 20090818L
Authority
NO
Norway
Prior art keywords
methods
herv
immune response
polypeptide compositions
endogenous retrovirus
Prior art date
Application number
NO20090818A
Other languages
English (en)
Norwegian (no)
Inventor
Mario Ostrowski
R Bradley Jones
Seth Rakoff-Nahoum
Douglas Nixon
Keith Garrison
Duncan Meiklejohn
Ashish Agrawal
Jack Lenz
Frederick M Hecht
Original Assignee
Seth Rakoff-Nahoum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seth Rakoff-Nahoum filed Critical Seth Rakoff-Nahoum
Publication of NO20090818L publication Critical patent/NO20090818L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
NO20090818A 2006-07-21 2009-02-20 Humant endogent retrovirus polypeptid sammensetninger samt anvendelsesmetoder derav NO20090818L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83246506P 2006-07-21 2006-07-21
PCT/US2007/016403 WO2008011120A2 (en) 2006-07-21 2007-07-19 Human endogenous retrovirus polypeptide compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
NO20090818L true NO20090818L (no) 2009-04-17

Family

ID=38957380

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090818A NO20090818L (no) 2006-07-21 2009-02-20 Humant endogent retrovirus polypeptid sammensetninger samt anvendelsesmetoder derav

Country Status (15)

Country Link
US (2) US20080171061A1 (es)
EP (1) EP2046380A4 (es)
JP (1) JP2009544614A (es)
KR (1) KR20090060410A (es)
CN (1) CN101557823A (es)
AU (1) AU2007275693A1 (es)
BR (1) BRPI0714714A2 (es)
CA (1) CA2658393A1 (es)
IL (1) IL196516A0 (es)
MX (1) MX2009000659A (es)
NO (1) NO20090818L (es)
RU (1) RU2009106089A (es)
SG (1) SG173997A1 (es)
WO (1) WO2008011120A2 (es)
ZA (1) ZA200900379B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2611960C (en) 2005-06-27 2015-05-05 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising n.meningitidis capsular saccharide conjugates
US20090297530A1 (en) * 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
EP2340851A4 (en) * 2008-09-18 2012-09-26 Univ Keio DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER
US20110250218A1 (en) * 2008-10-29 2011-10-13 Fong Lawrence H Disease-Associated Antigens and Methods of Use Thereof
US20130028933A1 (en) * 2009-12-28 2013-01-31 Ligocyte Pharmaceuticals, Inc. Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
KR102317399B1 (ko) 2012-01-26 2021-10-26 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
WO2014153114A1 (en) * 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP3478711B1 (en) * 2016-06-30 2022-10-12 The United States of America, as represented by the Secretary, Department of Health and Human Services Herv-e reactive t cell receptors and methods of use
JP2019528071A (ja) * 2016-08-23 2019-10-10 エイムヴィオン・アクティエセルスカブＡｉｍＶｉｏｎ Ａ／Ｓ 新規免疫刺激ペプチド
CA3049244A1 (en) 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
US20230241207A1 (en) * 2017-04-03 2023-08-03 Neon Therapeutics, Inc. Protein antigens and uses thereof
JP7277466B2 (ja) 2017-09-01 2023-05-19 インプラザー エー・ペー・エス 疾患の予防および／または治療における使用のためのワクチン
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
MX2021002519A (es) * 2018-09-06 2021-06-18 Centre Leon Berard Antigenos derivados de retrovirus endogeno humano tipo k (herv-k) como antigenos tumorales compartidos para vacuna anti-cancerigena.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
AU2002338856A1 (en) * 2001-09-06 2003-03-24 Novimmune S.A. Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination against sag
AT411262B (de) * 2001-09-27 2003-11-25 Wolff Klaus Dr Humanes endogenes retrovirus
WO2003050258A2 (en) * 2001-12-07 2003-06-19 Chiron Corporation Endogenous retrovirus polypeptides linked to oncogenic transformation
US20040096457A1 (en) * 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
EP1338606A1 (en) * 2002-02-22 2003-08-27 Magnus Von Knebel Doeberitz Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer
US20130108653A1 (en) * 2009-12-22 2013-05-02 Shervin Bahrami Bivalent molecules for hiv entry inhibition
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition

Also Published As

Publication number Publication date
KR20090060410A (ko) 2009-06-12
MX2009000659A (es) 2009-06-08
RU2009106089A (ru) 2010-08-27
US20080171061A1 (en) 2008-07-17
JP2009544614A (ja) 2009-12-17
EP2046380A4 (en) 2013-05-01
CN101557823A (zh) 2009-10-14
ZA200900379B (en) 2010-08-25
CA2658393A1 (en) 2008-01-24
EP2046380A2 (en) 2009-04-15
WO2008011120A2 (en) 2008-01-24
AU2007275693A1 (en) 2008-01-24
SG173997A1 (en) 2011-09-29
IL196516A0 (en) 2011-08-01
WO2008011120A3 (en) 2008-11-06
US20130323279A1 (en) 2013-12-05
BRPI0714714A2 (pt) 2013-04-09

Similar Documents

Publication Publication Date Title
NO20090818L (no) Humant endogent retrovirus polypeptid sammensetninger samt anvendelsesmetoder derav
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
JP2019146574A5 (es)
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
NO20063556L (no) HIV gp41 HR2-avledede syntetiske peptider og deres anvendelse ved behandling av human mangel pa immunitet mot virus
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
WO2006103666A3 (en) Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis
EA201190326A8 (ru) Полипептиды гормона роста и способы их получения и применения
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
NZ602351A (en) Axmi-115, axmi-113, axmi-005, axmi-163 and axmi-184 : vip3a insecticidal proteins from bacillus thuringiensis and methods for their use
IN2012DN02981A (es)
NZ576467A (en) Smoothened polypeptides and methods of use
NO20063026L (no) Antistoffer
RU2012157303A (ru) Адаптированная рекомбиназа для рекомбинации асимметричных участков-мишеней во множестве штаммов ретровирусов
EA202092589A2 (ru) Cxcr2-связывающие полипептиды
WO2004084805A3 (en) Acetylated tat polypeptides and methods of use thereof
BR112013003522A8 (pt) "polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, uso, método de preparação, bem como ácido nucleico codificando os mesmos"
WO2009038756A3 (en) Long interspersed nuclear element polypeptide compositions and methods of use thereof
EA201591213A1 (ru) Вакцины против вируса гепатита b
EA202090757A1 (ru) T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
WO2006046239A3 (en) A thymus-specific protein
WO2008151633A3 (en) Vectors for vaccines against lentivirus infections
DK1144600T3 (da) Akt-3-nukleinsyre, polypeptider og anvendelser deraf
WO2008113970A3 (en) Peptides

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application